drugset / Trial / NCT01333592
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.
Timeline
- Start
- —
- Primary completion
- 2012-08
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitiglinide | Small molecule | — | — |